Selective estrogen receptor modulators in chronic renal failure

Kidney International, Supplement

Volumn 63, Issue 85, 2003, Pages

  Weisinger, José R ^a   Pfeferman Heilberg, Ita ^b   Hernández, Eddy ^b   Carlini, Raul ^b   Bellorin Font, Ezequiel ^b  

^a HOSPITAL UNIVERSITARIO DE CARACAS   (Venezuela)

^b NONE

Author keywords

Bone mineral density; Hemodialysis; Hormone replacement therapy; Menopause; Osteoporosis; Raloxifene; Selective estrogen receptor modulator

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ALLELE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BREAST CANCER; CANCER INVASION; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DRUG EFFECT; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEMODIALYSIS; HOMOZYGOSITY; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPID METABOLISM; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RECEPTOR GENE; RENAL OSTEODYSTROPHY; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROKE; THROMBOEMBOLISM; TRABECULAR BONE; UREMIA; VEIN THROMBOSIS;

EID: 0037850076     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.63.s85.15.x     Document Type: Conference Paper

References (20)

1. GOODMAN WG, COBURN JW, SLATOPOLSKY E, SALUSKY IB: Renal osteodystrophy in adults and children, in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (4th ed), edited by Favus MJ, Philadelphia, Lippincott-Williams & Wilkins, 1999, pp 347-363
2. WEISINGER JR, GONZALEZ L, ALVAREZ H, et al: Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women. Kidney Int 58:331-335, 2000
3. COCHRANE R, REGAN L: Undetected gynecological disorders in women with renal disease. Human Reprod 12:667-670, 1997
4. HOLLEY JL, SCHMIDT RJ, BENDER FH, et al: Gynecological and reproductive issues in women on dialysis. Am J Kidney Dis 29:685-690, 1997
5. LINDBERG JS, MOE SM: Osteoporosis in end stage renal disease. Semin Nephrol 19:115-122, 1999
6. WEISINGER JR: Role of hormone replacement in the management of osteoporosis in hemodialyzed women: Perspectives for the future. Nephrol Dial Transplant 15(Suppl 5):36-37, 2000
7. PACIFICI R, RIFAS L, MCCRACKEN R, et al: Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc Natl Acad Sci USA 86:2398-2402, 1989
8. JONES TH: Interleukin-6, an endocrine cytokine. Clin Endocrinol 40:703-713, 1994
9. JILKA RL, HANGOC G, GIRASOLE G, et al: Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257:88-91, 1992
10. HOROWITZ M: Cytokines and estrogen in bone: Anti-osteoporotic effects. Science 260:626-627, 1993
11. NAVEH-MANY T, ALMOGI G, LIVNI N, SILVER J: Estrogen receptors, and biologic response in rat parathyroid tissue and C-cells. J Clin Invest 90:2434-2438, 1992
12. MATUSZKIEWICZ-ROWIÑSKA SK, RADOWICKI S, et al: The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol Dial Transplant 14:1238-1243, 1999
13. GINSBURG ES, OWEN WF, JR, GREENBERG L, et al: Estrogen absorption and metabolism in postmenopausal women with end-stage renal disease. J Clin Endocrinol Metab 81:4414-4417, 1996
14. WRITING GROUP FOR IHE WOMEN'S HEALIH INITIATIVE INVESTIGATORS: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 288:321-333, 2002
15. COSMAN F, LINDSAY R: Selective estrogen receptor modulators: Clinical spectrum. Endocr Rev 20:418-434, 1999
16. BJARNASON NH, HAARBO J, BYRJALSEN I, et al: Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 96:1964-1969, 1997
17. YANG NN, VENUGOPALAN M, HARDIKAR S, GLASEBROOK A: Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 273:1222-1225, 1996
18. KHOVIDHUNKIT W, SHOWACK DM: Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 130:431-439, 1999
19. ETTINGER B, BLACK DM, MITLAK BH, et al: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year: Randomized clinical trial. JAMA 282:637-645, 1999
20. RIGGS BL, MELTON J, III: Bone turnover matters: The raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17:11-17, 2002